LifeTech Scientific Corp
01302
Company Profile
Business description
LifeTech Scientific Corp develops and manufactures also responsible for marketing of of advanced minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of its revenue from China.
Contact
No. 22, Keji 12th Road South
14th Floor, LifeTech Scientific Building
High-tech Industrial Park
Nanshan District
Shenzhen518063
CHNT: +86 75586026250
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
1,392
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,816.40 | 58.90 | -0.66% |
| CAC 40 | 7,772.25 | 6.04 | 0.08% |
| DAX 40 | 24,177.48 | 117.19 | 0.49% |
| Dow JONES (US) | 44,203.89 | 180.60 | 0.41% |
| FTSE 100 | 8,971.22 | 32.90 | 0.37% |
| HKSE | 24,517.76 | 72.36 | -0.29% |
| NASDAQ | 20,699.44 | 21.64 | 0.10% |
| Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
| NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
| S&P 500 | 6,258.33 | 14.57 | 0.23% |
| S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
| SSE Composite Index | 3,503.78 | 1.22 | -0.03% |